Mylan introduces Hep C generic drug in India

Mylan Pharmaceuticals, an arm of Mylan N.V. announced that it has introduced its generic drug Harvoni which is a combination of Ledipasvir/Sofosbuvir under the brandname MyHep LVIRTM in the Indian market. Harvoni will be used for treating Hepatitis C infection. It provides a simplified Hepatitis C treatment regimen that removes the need for interferon and ribavirin. The product is also a single-tablet regimen and requires a therapy course of 12 weeks. Commenting on this, Rajiv Malik, President, Mylan said, “MyHep LVIRTM is an important addition to our growing Hepato Care segment in India that gives us the opportunity to offer patients the potential to be cured through a transformative and simplified single tablet, once-daily treatment regimen.”